Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.
|Published (Last):||5 June 2007|
|PDF File Size:||2.60 Mb|
|ePub File Size:||9.85 Mb|
|Price:||Free* [*Free Regsitration Required]|
Ranbaxy gets approval from Japan for Dewas unit; stk up 24 Jul 09 rsnbaxy The Company is in dialogue with these regulatory agencies and is addressing their concerns. If the shares are listed on more than one stock exchange, then the stock exchange where there is highest trading volume on the said date shall be considered.
However, considering the above matters relating to the Toansa manufacturing facility, provisions primarily relating to inventories, trade commitments, sales return etc. The effective portion of such cash fow hedges was recorded as part of reserves and surplus within hedging reserve and re-classifed in the Statement of Proft and Loss in the period corresponding to the occurrence of the highly probable forecasted transactions.
Segment information In accordance with AS 17, Segment Reporting, segment information has been given in the consolidated fnancial statements of the Company, and therefore, no separate disclosure on segment information is given in these fnancial statements.
Annual Reports & Presentations
The Company received the fnal assessment order from the AO in November whereby demand of Rs Annnual reports will not be deducted from your subscription. The amount is excluding interest and penalty, if any. The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India.
It is the largest exporter of bulk drugs and pharmaceutical dosag. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.
The amount above represents the difference payable. In calculating these provisions, the management has used the best information and estimates, presently available. Ranbaxy UK Limited, U.
As at 31 Marchthere are no such derivative contracts which are classifed as cash fow hedges. Please do try to use an alternate pdf reader geport case the file is unopenable with adobe.
Nifty bounces over ; Bharti languishes 17 Feb 10 The same is expected to be resumed shortly.
The Company has not accepted the same and has fled its objections before the DRP. Consequently, stock write off and other costs of Rs.
Ranbaxy Laboratories Balance Sheet, Ranbaxy Laboratories Financial Statement & Accounts
The Company has challenged the order before the Hon”ble Income Tax Appellate Tribunal ITAT and pending disposal of the matter, the management considers the amount of tax liability as unascertainable. Foreign funds hint at hiking India allocation 25 Mar 10 Pending disposal of the matter, the management considers the impact as unascertainable. Your Account is not yet activated Click here to receive activation mail once again. Please do reach out to us at contactus reportjunction.
Annual Reports | Sun Pharmaceutical Industries Ltd.
The following are the outstanding derivative contracts entered into by the Company: The Company is fully cooperating with this information request and is in dialogue with the US DOJ for submission of the requisite information. Description cannot exceed characters. Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs. ESOS provides that the grant price of options will amnual the latest available closing price on the stock exchange on which the shares of the Company are listed, prior to the date of the meeting of the Committee in which the options are granted.
The Company expects to resume API bulk shipments to EU countries from Toansa manufacturing facility upon receipt of clearances from relevant regulatory authorities.
Options lapse, if they are not exercised prior to the expiry date, which is ten years from the date of grant. Quick Links for ranbaxylaboratories. The amount recognised in the Statement of Proft and Loss represents consequential cost sales return, inventory write off and customer claim recognised by the Company. 20010-11
You will be annial to download it at any time during the subscription period. Hence, the Company has become a potentially sick company in terms of the provisions of Sick Industrial Companies Special Provisions Act, and requisite compliances under this Act would be made by the Company. Options are granted at the discretion of the committee to selected employees depending upon certain criterion.
ESOP – provides that the grant price will be the face value of the equity share. The options vests evenly over a period of three years from the date of grant.
The options vests evenly over a period of fve years from the date of grant. Ranbaxy Laboratories is not traded in the last 30 days. Related party disclosures A] Names of related parties Related parties where control exists with whom no transactions have taken place during the current period or previous year: Hedging and derivatives a The Company uses various forms of derivative instruments such as foreign exchange forward contracts including instruments which are in substance reporr contractsoptions, currency swaps, currency cum interest rate swaps and interest rate swaps to hedge its exposure to movements in foreign exchange and interest rates.
As per the Scheme, the share exchange ratio has been proposed ranbzxy 0. The sales consideration of Rs.
Since the matter involves signifcant judgement and in view of the inherent uncertainty of the present situation, the actual amounts may differ eventually.
ESOS I and II provide that the grant price of options is to be determined at the average of the daily closing price of the Company”s equity shares on the NSE during a period of 26 weeks preceding the date of the grant. RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms for human health careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents.
Commitments rreport Estimated amount of contracts remaining to be executed on capital account and not Options lapse, if they are not exercised prior to the expiry date, which is three months from the date of the vesting.